A team of researchers has come up with the all-new, next-generation immunotherapy for the treatment of cancer.A team of researchers at CHA Bundang Medical Center in South Korea has come up with an all-new treatment option that helps in overcoming the resistance issue that exists in the modern immunotherapeutic agents when it comes to cancer treatment.
The team of researchers was led by Professor Kim Chan & Jung Hong-Jae at the CHA Bundang Medical Center in Seongnam. During the study, the team was successful in overcoming the immunotherapeutic resistance by making use of a triple combination of immunotherapy –using the STING (Stimulators of Interferon Genes), the concept of immunotherapy, and cancer angiogenesis inhibitors.
The Study Involving the Concept of Immunotherapy
In the given study, STING serves to be the specialized in-vivo sensor that helps in detecting the invasion caused by cancer cells. The researchers were able to produce the given results after they had analyzed the cancer tissues of around 400 patients having intractable cancer.
During the study, the researchers observed that STING –usually acting as a sensor for recognizing cancer, is also known for expressing itself in the cancerous blood vessels. Moreover, it was also observed that STING has been closely associated with the immune response in the cancer cells or tumor.
The First-Ever Study to Develop the Next-Gen Immunotherapy
The given research is believed to be the first-ever instance in the world that proves the point that patients having increased STING expression can have improved therapeutic prognosis. The team also confirmed that around 60 percent of the patients –witnessing zero response to the immunotherapies due to issues related to resistance, were able to show complete cancer remission when the given team had administered the unique triple combination immunotherapy.
The researchers said in a news release that the all-new treatment was capable of maintaining the given immunosuppressive effect for a longer period and also helped in prolonging the survival rate. Professor Kim explained that the research has been successful in identifying a new immunotherapeutic strategy that aims at enhancing the overall efficacy of the respective immunotherapeutic agents, including CTLA-4 and PD-1 immunostimulants.
Immunotherapy that makes use of the revolutionary STING agonists might turn to be a highly effective treatment option for intractable cancer types, including pancreatic cancer, stomach cancer, liver cancer, kidney cancer, and bladder cancer.